Could the choice of diabetes medication change a patient’s cardiovascular risk?

Update: 2025-10-22

Description

A large real-world study of over 1.2 million adults with type 2 diabetes found that SGLT2 inhibitors and GLP-1 receptor agonists reduced major cardiovascular events compared with metformin, while sulfonylureas and insulin increased risk. A separate French population study showed no association between first-trimester mRNA COVID-19 vaccination and congenital malformations, supporting vaccine safety in pregnancy. Finally, researchers at Mass General Brigham reported that large language models can produce “sycophantic” but incorrect medical advice, emphasizing the need for clinician oversight when using AI in healthcare.

Comments

In Channel

Emerging Therapeutics and Biosimilars: Advancing the Future of Osteoporosis Care

2025-11-2708:34

Sequential Therapy and Switching Strategies in Osteoporosis: Insights for Improved Outcomes

2025-11-2607:03

How much can staying active in adulthood realy cut dementia risk?

2025-11-2505:41

Advanced Imaging in Osteoporosis: Integrating Trabecular Bone Score for Enhanced Fracture Risk Assessment

2025-11-2407:37

How are major medical societies responding to FDA changes to menopause therapy labels?

2025-11-2005:03

Could over-the-counter painkillers truly outperform opioids after dental surgery?

2025-11-1304:50

Managing CNS Involvement in HER2+ Lung Cancer

2025-11-0511:57

Could a chemo-free regimen surpass the standard triplet in HER2+ Breast Cancer?

2025-11-0405:09

Evolving Second-Line Strategies in HER2+ Lung Cancer

2025-11-0311:44

First-Line Strategies in HER2+ Lung Cancer

2025-10-3114:53

Can HER2+ Metastatic Breast Cancer Be Cured?

2025-10-3015:00

What the PATINA Trial Teaches Us About Treating HER2+ Breast Cancer

2025-10-2909:58

Could there be a long-awaited breakthrough in first-line therapy for triple-negative breast cancer?